Skip to main content
Erschienen in: Infection 4/2013

01.08.2013 | Clinical and Epidemiological Study

Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989–2010)

verfasst von: S. Ben-Shimol, R. Dagan, Y. Schonmann, N. Givon-Lavi, N. Keller, C. Block, I. Kassis, M. Ephros, D. Greenberg

Erschienen in: Infection | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Aim

To describe the dynamics in the incidence of childhood invasive meningococcal disease (IMD) in Israel during a 22-year period (1989–2010).

Methods

A longitudinal prospective surveillance in all 27 medical centers with pediatric services in Israel. All cases of children <15 years old with positive blood/cerebrospinal fluid (CSF) culture for Neisseria meningitidis were reported. Demographic, clinical, and bacteriological data were recorded. Meningococcal vaccine was not routinely given to Israeli children during the study period.

Results

The mean age ± standard deviation (SD) among the 743 cases was 40.7 ± 40.2 months. The mean yearly incidence/100,000 was 2.0 ± 0.8. Age-specific incidences were 8.7 ± 2.8, 2.9 ± 1.5, and 0.8 ± 0.5 for children <1, 1–4, and >4 years old, respectively. The overall incidence decreased significantly from 3.7 in 1989 to 1.5 in 2010. Meningitis constituted 69.2 % of all cases. The most common serogroups were: B (76.9 %), C (10.9 %), Y (8.0 %), and W135 (2.9 %). 78.6 % of all serogroup B isolates were from children <5 years old (p < 0.01). Serogroup C was found mainly in children ≥5 years old (63.4 %). The case fatality rates (CFRs) for children <1, 1–4, >4 years old, and the total study population were 9.2, 12.3, 7.7, and 9.9 %, respectively. CFRs were higher for children without meningitis (14.9 %) compared to children with meningitis (7.9 %) (p < 0.01).

Conclusions

Overall, and for serogroups B and W135, childhood IMD rates decreased significantly in Israel during the study period, without routine vaccine usage. The most common serogroup in all age groups was B, which was most prevalent in children <5 years old. No change in the trend of the overall CFR was noted during the study period.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378–88.CrossRefPubMed Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378–88.CrossRefPubMed
2.
Zurück zum Zitat American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics. 2005;116:496–505.CrossRef American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics. 2005;116:496–505.CrossRef
3.
Zurück zum Zitat Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692–700.CrossRefPubMed Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692–700.CrossRefPubMed
4.
Zurück zum Zitat Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19:142–64.CrossRefPubMed Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19:142–64.CrossRefPubMed
5.
Zurück zum Zitat Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27:B51–63.CrossRefPubMed Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27:B51–63.CrossRefPubMed
6.
Zurück zum Zitat Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369:2196–210.CrossRefPubMed Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369:2196–210.CrossRefPubMed
7.
Zurück zum Zitat Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M. Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect. 2011;15:1–19. Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M. Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect. 2011;15:1–19.
8.
Zurück zum Zitat Taha MK, Achtman M, Alonso JM, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet. 2000;356:2159.CrossRefPubMed Taha MK, Achtman M, Alonso JM, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet. 2000;356:2159.CrossRefPubMed
9.
Zurück zum Zitat Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009;27:B30–41.CrossRefPubMed Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009;27:B30–41.CrossRefPubMed
10.
Zurück zum Zitat Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis. 2005;5:21–30.CrossRefPubMed Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis. 2005;5:21–30.CrossRefPubMed
11.
Zurück zum Zitat Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac™. Hum Vaccin Immunother. 2012;8:715–24.CrossRefPubMed Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac™. Hum Vaccin Immunother. 2012;8:715–24.CrossRefPubMed
12.
Zurück zum Zitat Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717–22.PubMed Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717–22.PubMed
13.
Zurück zum Zitat Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines—an unfinished story. Lancet Infect Dis. 2010;10:112–24.CrossRefPubMed Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines—an unfinished story. Lancet Infect Dis. 2010;10:112–24.CrossRefPubMed
14.
Zurück zum Zitat Keiser PB, Biggs-Cicatelli S, Moran EE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine. 2011;29:1413–20.CrossRefPubMed Keiser PB, Biggs-Cicatelli S, Moran EE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine. 2011;29:1413–20.CrossRefPubMed
15.
Zurück zum Zitat Keiser PB, Gibbs BT, Coster TS, et al. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine. 2010;28:6970–6.CrossRefPubMed Keiser PB, Gibbs BT, Coster TS, et al. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine. 2010;28:6970–6.CrossRefPubMed
16.
Zurück zum Zitat Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines. 2011;10:575–88.CrossRefPubMed Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines. 2011;10:575–88.CrossRefPubMed
17.
Zurück zum Zitat Mor Z, Srur S, Dagan R, Rishpon S. Hepatitis A disease following the implementation of universal vaccination: who is at risk? J Viral Hepat. 2010;17:293–7.CrossRefPubMed Mor Z, Srur S, Dagan R, Rishpon S. Hepatitis A disease following the implementation of universal vaccination: who is at risk? J Viral Hepat. 2010;17:293–7.CrossRefPubMed
18.
Zurück zum Zitat Stein-Zamir C, Abramson N, Zentner G, Shoob H, Valinsky L, Block C. Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect. 2008;136:782–9.PubMed Stein-Zamir C, Abramson N, Zentner G, Shoob H, Valinsky L, Block C. Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect. 2008;136:782–9.PubMed
19.
Zurück zum Zitat Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect. 1994;112:115–24.CrossRefPubMed Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect. 1994;112:115–24.CrossRefPubMed
20.
Zurück zum Zitat Paret G, Keller N, Barzilai A, et al. Invasive meningococcal disease: patient and strain characteristics set new challenge for prevention and control. Infection. 1999;27:261–4.CrossRefPubMed Paret G, Keller N, Barzilai A, et al. Invasive meningococcal disease: patient and strain characteristics set new challenge for prevention and control. Infection. 1999;27:261–4.CrossRefPubMed
21.
Zurück zum Zitat National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing; Fifteenth informational supplement. CLSI document M100-S15. Wayne, PA: NCCLS; 2005. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing; Fifteenth informational supplement. CLSI document M100-S15. Wayne, PA: NCCLS; 2005.
22.
Zurück zum Zitat Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1–21.PubMed Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1–21.PubMed
23.
Zurück zum Zitat Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis. 1999;180:1894–901.CrossRefPubMed Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis. 1999;180:1894–901.CrossRefPubMed
24.
Zurück zum Zitat Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics. 2006;118:e979–84.CrossRefPubMed Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics. 2006;118:e979–84.CrossRefPubMed
26.
Zurück zum Zitat Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. 2004;23:S274–9.PubMed Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. 2004;23:S274–9.PubMed
27.
Zurück zum Zitat Heyderman RS, Ben-Shlomo Y, Brennan CA, Somerset M. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child. 2004;89:1064–8.CrossRefPubMed Heyderman RS, Ben-Shlomo Y, Brennan CA, Somerset M. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child. 2004;89:1064–8.CrossRefPubMed
28.
Zurück zum Zitat Stanwell-Smith RE, Stuart JM, Hughes AO, et al. Smoking, the environment and meningococcal disease: a case control study. Epidemiol Infect. 1994;112:315–28.CrossRefPubMed Stanwell-Smith RE, Stuart JM, Hughes AO, et al. Smoking, the environment and meningococcal disease: a case control study. Epidemiol Infect. 1994;112:315–28.CrossRefPubMed
29.
Zurück zum Zitat Stuart JM, Cartwright KA, Dawson JA, Rickard J, Noah ND. Risk factors for meningococcal disease: a case control study in south west England. Community Med. 1988;10:139–46.PubMed Stuart JM, Cartwright KA, Dawson JA, Rickard J, Noah ND. Risk factors for meningococcal disease: a case control study in south west England. Community Med. 1988;10:139–46.PubMed
30.
Zurück zum Zitat Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184–91.CrossRefPubMed Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184–91.CrossRefPubMed
31.
Zurück zum Zitat Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis. 1998;177:497–500.CrossRefPubMed Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis. 1998;177:497–500.CrossRefPubMed
32.
Zurück zum Zitat Stoddard J, Dougherty N. Universal immunization of infants against Neisseria meningitidis: addressing the remaining unmet medical need in the prevention of meningitis and septicemia. Hum Vaccin. 2010;6:219–33.CrossRefPubMed Stoddard J, Dougherty N. Universal immunization of infants against Neisseria meningitidis: addressing the remaining unmet medical need in the prevention of meningitis and septicemia. Hum Vaccin. 2010;6:219–33.CrossRefPubMed
33.
Zurück zum Zitat Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis. 2009;49:597–605.CrossRefPubMed Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis. 2009;49:597–605.CrossRefPubMed
34.
35.
Zurück zum Zitat Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine. 2001;19:2924–31.CrossRefPubMed Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine. 2001;19:2924–31.CrossRefPubMed
36.
Zurück zum Zitat Cohn AC, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants. JAMA. 2012;307:614–5.CrossRefPubMed Cohn AC, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants. JAMA. 2012;307:614–5.CrossRefPubMed
Metadaten
Titel
Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989–2010)
verfasst von
S. Ben-Shimol
R. Dagan
Y. Schonmann
N. Givon-Lavi
N. Keller
C. Block
I. Kassis
M. Ephros
D. Greenberg
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 4/2013
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0439-6

Weitere Artikel der Ausgabe 4/2013

Infection 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.